Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer

Hiraike,Haruko; Wada-Hiraike,Osamu; Nakagawa,Shunsuke; Saji,Shigehira; Maeda,Daichi; Miyamoto,Yuichiro; Sone,Kenbun; Tanikawa,Michihiro; Oda,Katsutoshi; Nakagawa,Keiichi; Yano,Tetsu; Fukayama,Masashi; Taketani,Yuji

doi:10.3892/etm.2011.333

Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer

Authors:
- Haruko Hiraike
- Osamu Wada-Hiraike
- Shunsuke Nakagawa
- Shigehira Saji
- Daichi Maeda
- Yuichiro Miyamoto
- Kenbun Sone
- Michihiro Tanikawa
- Katsutoshi Oda
- Keiichi Nakagawa
- Tetsu Yano
- Masashi Fukayama
- Yuji Taketani
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan, Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo 113-8677, Japan, Department of Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan, Department of Radiology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan
Published online on: August 12, 2011 https://doi.org/10.3892/etm.2011.333
Pages: 1105-1109

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DBC1/KIAA1967 (deleted in breast cancer 1) is a putative tumor-suppressor gene cloned from breast cancer specimens and is reported to regulate p53-dependent apoptosis through its specific inhibition of SIRT1 deacetylase. Although SIRT1 plays a pivotal role in carcinogenesis by regulating cellular proliferation, survival and death, its role in breast cancer remains controversial. Therefore, we aimed to investigate the expression status and clinicopathological significance of DBC1 and SIRT1 in breast cancer tissues. We evaluated the expression of DBC1 and SIRT1 in breast core-needle biopsy specimens from 48 primary breast cancer patients between 2005 and 2008. These patients were treated with primary systemic chemotherapy and subsequent surgical resection of the lesions. Immunohistochemical expression scores of DBC1 and SIRT1 were evaluated, and the relationship between their expression levels and clinicopathological features of breast cancer was analyzed. The expression was observed exclusively in the nuclei of normal and neoplastic ductal cells. In breast biopsy specimens, positive expression of DBC1 and SIRT1 was noted in 85 and 98% of patients, respectively. Expression of DBC1 was significantly associated with the tumor nuclear grade (P=0.019). DBC1 and SIRT1 expression was inversely correlated with HER2 expression (P=0.026 and 0.003, respectively). Lower expression of DBC1 and SIRT1 indicated a tendency for a favorable pathological response to chemotherapy, although this was not statistically significant. Our results reveal that the expression of DBC1 and SIRT1 in breast tissues is associated with tumor characteristics.

View Figures

View References

1	Hamaguchi M, Meth JL, von Klitzing C, et al: DBC2, a candidate for a tumor-suppressor gene involved in breast cancer. Proc Natl Acad Sci USA. 99:13647–13652. 2002. View Article : Google Scholar
2	Cha EJ, Noh SJ, Kwon KS, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
3	Sung JY, Kim R, Kim JE and Lee J: Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci. 101:1738–1744. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lee H, Kim KR, Noh SJ, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol. 42:204–213. 2011. View Article : Google Scholar : PubMed/NCBI
5	Kim JE, Chen J and Lou Z: DBC1 is a negative regulator of SIRT1. Nature. 451:583–586. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhao W, Kruse JP, Tang Y, et al: Negative regulation of the deacetylase SIRT1 by DBC1. Nature. 451:587–590. 2008. View Article : Google Scholar : PubMed/NCBI
7	Sundararajan R, Chen G, Mukherjee C and White E: Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling. Oncogene. 24:4908–4920. 2005. View Article : Google Scholar
8	Hiraike H, Wada-Hiraike O, Nakagawa S, et al: Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer. 102:1061–1067. 2010. View Article : Google Scholar : PubMed/NCBI
9	Koyama S, Wada-Hiraike O, Nakagawa S, et al: Repression of estrogen receptor beta function by putative tumor suppressor DBC1. Biochem Biophys Res Commun. 392:357–362. 2010. View Article : Google Scholar : PubMed/NCBI
10	Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004. View Article : Google Scholar : PubMed/NCBI
11	Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kabra N, Li Z, Chen L, et al: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem. 284:18210–18217. 2009. View Article : Google Scholar : PubMed/NCBI
13	Jang KY, Kim KS, Hwang SH, et al: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 41:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zhang Y, Zhang M, Dong H, et al: Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene. 28:445–460. 2009. View Article : Google Scholar : PubMed/NCBI
15	Vaziri H, Dessain SK, Ng Eaton E, et al: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159. 2001. View Article : Google Scholar : PubMed/NCBI
16	Wong S and Weber JD: Deacetylation of the retinoblastoma tumour-suppressor protein by SIRT1. Biochem J. 407:451–460. 2007. View Article : Google Scholar : PubMed/NCBI
17	Oberdoerffer P, Michan S, McVay M, et al: SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 135:907–918. 2008. View Article : Google Scholar : PubMed/NCBI
18	Japanese Pathological Response Criteria of Breast Cancer: General Rules for Clinical and Pathological Recording of Breast Cancer (15th edition). 75–76. 2008.
19	Kurosumi M, Akashi-Tanaka S, Akiyama F, et al: Histopatho-logical criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 15:5–7. 2008. View Article : Google Scholar : PubMed/NCBI
20	Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999.
21	Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
22	Tsuda H, Akiyama F, Kurosumi M, et al: Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol. 28:486–491. 1998. View Article : Google Scholar
23	Trauernicht AM, Kim SJ, Kim NH and Boyer TG: Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol Endocrinol. 21:1526–1536. 2007. View Article : Google Scholar : PubMed/NCBI
24	Richardson AL, Wang ZC, de Nicolo A, et al: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI